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Abstract
A recent genome-wide association study (GWAS) identified association with variants in X-
linked CLDN2 andMORC4, and PRSS1-PRSS2 loci with chronic pancreatitis (CP) in North
American patients of European ancestry. We selected 9 variants from the reported GWAS
and replicated the association with CP in Indian patients by genotyping 1807 unrelated Indi-
ans of Indo-European ethnicity, including 519 patients with CP and 1288 controls. The etiol-
ogy of CP was idiopathic in 83.62% and alcoholic in 16.38% of 519 patients. Our study
confirmed a significant association of 2 variants in CLDN2 gene (rs4409525—OR 1.71, P =
1.38 x 10-09; rs12008279—OR 1.56, P = 1.53 x 10-04) and 2 variants inMORC4 gene
(rs12688220—OR 1.72, P = 9.20 x 10-09; rs6622126—OR 1.75, P = 4.04x10-05) in Indian
patients with CP. We also found significant association at PRSS1-PRSS2 locus (OR 0.60; P
= 9.92 x 10-06) and SAMD12-TNFRSF11B (OR 0.49, 95% CI [0.31–0.78], P = 0.0027). A
variant in the geneMORC4 (rs12688220) showed significant interaction with alcohol (OR
for homozygous and heterozygous risk allele -14.62 and 1.51 respectively, P = 0.0068) sug-
gesting gene-environment interaction. A combined analysis of the genes CLDN2 and
MORC4 based on an effective risk allele score revealed a higher percentage of individuals
homozygous for the risk allele in CP cases with 5.09 fold enhanced risk in individuals with 7
or more effective risk alleles compared with individuals with 3 or less risk alleles (P = 1.88 x
10-14). Genetic variants in CLDN2 andMORC4 genes were associated with CP in Indian
patients.
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Introduction
Chronic pancreatitis (CP) is a progressive and irreversible inflammatory disorder of pancreas
leading to abdominal pain, diabetes and exocrine insufficiency. The prevalence of CP varies
from 10 to 125/100000 individuals in different countries and is reported to be on much higher
side in Indian population [1]. Various risk factors for CP are known such as alcohol, smoking,
hereditary, metabolic but etiology is not known in the majority of patients termed as having
Idiopathic chronic pancreatitis (ICP) [2, 3]. Even in those with known risk factors, the role is
not fully explained by the injurious agent such as alcohol, as most other individuals with same
risk factor do not develop CP. Thus, genetic susceptibility has been suggested to play an impor-
tant role in etiopathogenesis of CP [4].
Indeed, starting with cationic trypsinogen gene (PRSS1) mutations in hereditary pancreati-
tis, mutations in many other genes predominantly SPINK1, CFTR, chymotrypsin C, CPA1, CEL
etc. have been reported in patients with CP [5–9]. The risk susceptibility for CP cannot be fully
explained by known genetic mutations. In this regard, a genome wide association study
(GWAS) on pancreatitis identified polymorphisms at X-linked CLDN2 locus being robustly
associated with recurrent acute pancreatitis and predominantly alcohol-related chronic pan-
creatitis in North American patients of European ancestry [10].
Studies have reported various genetic variations in SPINK1, CFTR, Cathepsin B and chymo-
trypsin C genes being associated with CP in Indian patients [11–14]. However, these associa-
tions particularly of SPINK1 gene are found in only up to 30–40% of patients and do not
explain the disease risk in the majority of patients.
Various studies had revealed that genetic constitution of Indian population differs from
other major ethnic population of the world [15]. Therefore, genes associated with a disorder in
other populations need to be evaluated for their role in Indian population. In present study, we
investigated recently identified GWAS variants associated with pancreatitis [10], in 1807 unre-
lated Indian individuals of Indo-European ethnicity for their association with CP.
Methods
Ethics Statement
Prior informed written consent was obtained from both patient and healthy control partici-
pants. The study was approved by the Human Ethics Committee of CSIR-Institute of Geno-
mics and Integrative Biology, All India Institute of Medical Sciences research Ethics
Committee; Ethics Committee of Post-graduate Institute of Medical Education and Research,
Chandigarh; Sanjay Gandhi Post-graduate Institute of Medical Sciences research Ethics Com-
mittee, Lucknow and Institute of Post-graduate Medical Education and Research Ethics Com-
mittee, Kolkata. The study was conducted in accordance with the principles of Helsinki
Declaration.
Study design
This study involved 1807 unrelated Indian individuals of Indo-European ethnicity, including
519 patients with CP and 1288 ethnically matched healthy controls. Among the 519 CP
patients, 434 subjects were with ICP and 85 were with Alcoholic chronic pancreatitis (ACP).
The case subjects were recruited from the Departments of Gastroenterology at the following
centers: All India Institute of Medical Sciences, New Delhi; Post-graduate Institute of Medical
Education and Research, Chandigarh; Sanjay Gandhi Post-graduate Institute of Medical Sci-
ences, Lucknow and Institute of Post-graduate Medical Education and Research, Kolkata by
INDIPAN (Indian Consortium for Pancreatitis) members. The diagnosis and etiology of CP
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were made as described previously by Midha et al., 2009 [12]. Briefly, the diagnosis was made
in the appropriate clinical setting if there was evidence of pancreatic duct dilatation and irregu-
larity and/or pancreatic calcification on imaging studies that included ultrasonography, endo-
scopic retrograde cholangiopancreatography (ERCP); contrast enhanced computed
tomography (CECT) scan, and/or magnetic resonance cholangiopancreatography (MRCP).
The etiology of CP was determined as follows: (a) Alcoholic CP: If a patient was drinking>60
g (females) or>80 g (males) of alcohol per day for>5 years, (b) Hereditary CP: If>2 first-
degree relatives were suffering from CP with an autosomal dominant pattern of inheritance;
and those without autosomal dominant inheritance were labeled as familial chronic pancreati-
tis (c) Metabolic: If there was evidence of hyperparathyroidism or hypertriglyceridemia, (d)
Traumatic: If there was a history of definite abdominal trauma with imaging evidence of pan-
creatic injury and subsequent ductal dilatation, and (e) Idiopathic: If no definite cause of CP
was identified.
All control subjects of the current study are part of the INDICO (Indian Diabetes Consor-
tium) [16]. The inclusion and exclusion criteria for control subjects were as described earlier
[15], controls were 40 years aged healthy persons with no family history of diabetes and no
visible symptoms of pancreatitis. They had fasting glucose level<110mg/dl and HbA1c
level 6%. All patients underwent a detailed questionnaire based evaluation and extensive
diagnostic work-up. In particular, data regarding age at onset of pancreatitis, age at diagnosis,
duration of disease, family history of pancreatitis and known risk factors for chronic pancreati-
tis such as alcohol and smoking, and complications of CP such as diabetes were recorded.
Genotyping
Out of the 11 SNPs (S1 Table) (p value<10-7 for the stage 1 or stage 2 or combined analysis)
reported by Whitcomb et al. [10], 9 were taken for genotyping including two proxy SNPs. Two
SNPs (rs7057398 and rs5917027) were not included in the study because these did not get mul-
tiplexed. Two proxies (rs12012022, proxy for rs12014762 and rs1985888/rs2855983, proxy for
rs10273639) were used in this study because the original SNPs did not get multiplexed. Two
SNPs (rs1985888 and rs2855983) were in LD with each other. Finally, we worked with 9 SNPs
for all analysis. Genotyping of the cases was done using SequenomMassARRAY1 system
(iPLEX GOLD) (Sequenom, San Diego, CA, USA) following the manufacturer’s protocol and
controls were genotyped on Illumina Human610-Quad Bead Chips (Illumina Inc., San Diego,
CA). The quality control of genotype data has been as reported earlier [15]. Some of control
samples (~3%) were genotyped using Sequenom MassARRAY1 to determine consistency in
genotyping platforms and>95% genotype consistency was observed in both platforms. The
genotype results of each plate were accepted only if the concordance rate of>99% was
observed among duplicates. Quality control criteria for the SNPs to qualify for further analysis
included: minor allele frequency (MAF)0.05, missingness per SNP<5% and no significant
deviation from the Hardy-Weinberg equilibrium (HWE).
Statistical analysis
Association of the SNPs with CP was investigated for the whole group of CP patients and also
separately for ICP and ACP. Genotype distribution for all SNPs was analyzed for deviation
from HWE using χ2 analysis. Logistic regression analysis, assuming log additive model, to
determine the association between SNPs and the risk for CP was performed. The associations
were adjusted for sex and age as appropriate and OR with 95% CI are presented with respect to
the allele as reported in initial study [10]. A P value of<0.0055 (α = 0.05/9) for 9 independent
SNPs was considered significant for association with CP after Bonferroni correction for
CLDN2 andMORC4Gene Polymorphisms and Chronic Pancreatitis
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multiple testing. Association analysis was performed using following categories: ACP and ICP
combined, ICP alone and ACP alone versus controls. For analysis of sex chromosome SNPs,
male hemizygous genotypes were assumed as equivalent to female homozygous genotypes and
coded as 0 and 2 for computational ease. As PLINK sets the count of minor alleles in males as 0
and 1, and includes a sex effect, using above coding has no impact on association tests based on
logistic regression [17]. SNPs with OR<1 are considered protective while those with OR>1
are considered as conferring risk for the disease. The combined effect of the SNPs on the risk of
CP was assessed by computing effective number of risk alleles, as described earlier [18]. Briefly,
only SNPs with p<0.0055 (corrected P value) were used to calculate effective number of risk
alleles. The weighted risk given by SwiXi/Swi (where Xi is the genotype coding for the i
th SNP
as provided above and wi is the logarithm of the odds Ratio corresponding to that SNP) was
multiplied by 14 (maximum possible number of risk alleles corresponding to 7 SNPs found sig-
nificant in present study) to obtain the ‘effective’ number of risk alleles. The combined risk
analysis for CLDN2 andMORC4 genes was based on 4 SNPs and hence, effective number of
risk alleles was obtained by multiplying weighted risk by 8. We note that while the maximum
number of risk alleles at these 4 SNPs can only be 4 for males, the coding of 0 or 2 for hemizy-
gous male genotypes allow for effective number of risk alleles to be computed as above. The
analysis included only those individuals whose genotypes at all 7 SNPs (or 4 for CLDN2 and
MORC4 locus) were available. Considering the individuals with<5 risk alleles as the reference
(or<3 for CLDN2 andMORC4 locus), ORs and P values for increase in disease risk with each
‘effective’ risk allele were calculated after adjusting for age and sex. With adjustment for sex,
the results of combined risk analysis would be identical to those obtained when effective num-
ber of risk alleles is computed based on the actual number of risk alleles at 4 SNPs (that is, by
coding male hemizygous genotypes as 0 or 1). The genotype information of samples for studied
SNPs has been given in S4 Table.
To further rule out the possibility of spurious association because of coding of male hemizy-
gote as being male homozygote, sex matched case control analysis was performed for both
ACP and ICP combined samples and ICP samples separately and meta-analysis of the sum-
mary statistics were done.
Gene-environment interaction of alcohol and smoking, with CP was estimated using gener-
alized linear models (additive model using CGEN package in R). For 3 SNPs (rs11988997,
rs12008279, rs6622126), above model did not fit and data for interaction with alcohol were
analyzed under a recessive mode of inheritance and an additive risk model comprising the
main effects of genotype, alcohol consumption and their interaction effect. Additionally, the
interaction of SNP (rs11988997) with smoking was also analyzed using a similar additive risk
model and χ2 test was used to determine significance of combined effect of SNPs at CLDN2
andMORC4 locus with CP. Statistical analyses were performed using R (version 3.0.1) and
PLINK (http://pngu.mgh.harvard.edu/purcell/plink/).
Results
Study demographics
Of the 519 patients with CP, 434 had ICP and 85 had ACP as shown in Table 1. Patients with
ICP developed disease at a significantly younger age (mean age at onset 23.42 years) compared
with ACP patients (mean age 37.58 years; p<0.0001). Of the patients with ICP, 63.36% were
males while all ACP patients were males, compared to 53.42% males in the controls (Table 1).
Association analysis for CP (ACP and ICP combined) vs. controls. Comparing CP vs.
controls, 4 genetic variations in X-linked CLDN2 andMORC4 genes showed significant associ-
ation with CP and remained so even after adjustment for age and sex (Table 2). The gene
CLDN2 andMORC4Gene Polymorphisms and Chronic Pancreatitis
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variant forMORC4 conferred highest susceptibility at rs12688220 (OR—1.72; 95% CI [1.43–
2.06], P = 9.20 x 10-09) and at rs6622126 (OR—1.75, 95% CI [1.34–2.28], P = 4.04 x 10-05).
Another variant at rs12012022 had an OR of 1.27 (95% CI [1.05–1.53]) but did not reach
required statistical significance (P = 0.012). Two variants for CLDN2 gene at rs4409525 (OR—
1.71, 95% CI [1.44–2.04]; P = 1.38 x 10-09) and at rs12008279 (OR—1.56, 95% CI [1.24–1.96];
P = 1.53 x 10-04) also conferred significant risk. Furthermore, another variant at rs379742 for
MUM1L1-CXorf57 was also found to be significantly associated with CP (OR 1.32, 95% CI
[1.11–1.58]; P = 0.0023), that is in consistence with earlier reports.
We also found significant association at PRSS1-PRSS2 locus with OR 0.60 (95% CI [0.48–
0.76], P = 9.92 x 10-06) as protective for CP. In addition, another variant at rs11988997 for
SAMD12-TNFRSF11B was also found to be protective (OR 0.49, 95% CI [0.31–0.78];
P = 0.0027). Sex-stratified analysis also showed similar results as shown in S2 Table.
Table 1. Demographic data of patients with ICP, ACP and controls used in the study.
Controls Cases
ICP ACP
Variable n n n
n (men/women) 1288 688/600 434 275/159 85 85/0
Age (years)ⱡ 1288 52.61 ± 10.37 432 30.12 ± 11.12* 78 42.78 ± 8.72*
Age of onset (years)ⱡ - 410 23.42 ± 11.03 78 37.58 ± 8.72**
Alcohol consumption (%) 1286 192 (14.93) 410 22 (5.37) 85 85 (100)
Smoking (%) 1285 324 (25.21) 281 14 (4.98) 76 62 (81.58)
Tobacco chewing (%) 1285 168 (13.07) 281 7 (2.49) 76 8 (10.53)
n = Total number of samples with measured phenotype, ⱡdata are mean ± SD,
*p value <0.0001 showing significance vs. controls,
**p value<0.0001 showing significance vs. ICP cases.
doi:10.1371/journal.pone.0147345.t001
Table 2. Association of SNPs with CP (n = 519) and control (n = 1288) subjects.
CHR Gene (SNP) A1* A2 Frequency OR (95%CI) SE Punadj OR (95%CI) SE Padj
Cases Controls
7 PRSS1-PRSS2 (rs2855983) A G 0.56 0.66 0.66 (0.57–0.76) 0.08 3.50 x 10-08 0.60 (0.48–0.76) 0.11 9.92 x 10-06
8 SAMD12-TNFRSF11B (rs11988997) T C 0.06 0.09 0.57 (0.42–0.78) 0.16 3.61 x 10-04 0.49 (0.31–0.78) 0.24 2.70 x 10-03
10 KIAA1462-MTPAP (rs2995271) C T 0.39 0.35 1.20 (1.03–1.40) 0.08 0.02 1.21 (0.96–1.52) 0.12 0.11
X MUM1L1-CXorf57 (rs379742) T C 0.45 0.32 1.47 (1.30–1.66) 0.06 1.03 x 10-09 1.32 (1.11–1.58) 0.09 2.30 x 10-03
X CLDN2 (rs4409525) A G 0.70 0.49 1.84 (1.62–2.08) 0.06 5.71 x 10-22 1.71 (1.44–2.04) 0.09 1.38 x 10-09
X CLDN2 (rs12008279) G A 0.89 0.73 2.05 (1.71–2.46) 0.09 7.27 x 10-15 1.56 (1.24–1.96) 0.12 1.53 x 10-04
X MORC4 (rs12012022) T C 0.36 0.25 1.44 (1.27–1.64) 0.07 1.87 x 10-08 1.27 (1.05–1.53) 0.09 0.01
X MORC4 (rs6622126) A G 0.89 0.72 2.42 (1.95–3.01) 0.11 1.16 x 10-15 1.75 (1.34–2.28) 0.14 4.04 x 10-05
X MORC4 (rs12688220) T C 0.73 0.48 1.96 (1.71–2.24) 0.07 3.41 x 10-22 1.72 (1.43–2.06) 0.09 9.20 x 10-09
* Effect sizes of the present study are presented with respect to the reported allele (A1) in the source study, for proxy SNPs the allele on same strand as
that of reported allele has been used. Significance achieved at P = 0.05/9 (α = 0.0055) after Bonferroni correction.
CHR = chromosome, SNP = single nucleotide polymorphism, A2 = Other allele, OR = odds ratio, CI = confidence interval, SE = Standard error,
Punadj = unadjusted analysis and Padj = adjusted analysis for covariates. Analysis is adjusted for sex and age.
doi:10.1371/journal.pone.0147345.t002
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Association analysis for ICP vs. controls. In patients with ICP, all 5 variants at X-linked
CLDN2 andMORC4 genes retained significant association with susceptibility to ICP with ORs
ranging from 1.41 to 2.42 and P values ranging from 9.85 x 10-07 to 1.24 x 10-19 (Table 3). Fol-
lowing adjustment for age and sex, variants at rs6622126 (OR 1.62, 95% CI [1.16–2.25];
P = 0.0042), rs4409525 (OR 1.57, 95% CI [1.28–1.93]; P = 1.36 x 10-05) and rs12688220 (OR
1.50, 95% CI [1.20–1.87]; P = 2.98 x 10-04) had significant association with ICP.
We also found that the variant rs2855983 at PRSS1-PRSS2 locus was significantly associated
in ICP patients similar to its status in the combined analysis (OR 0.63, 95% CI [0.49–0.82];
P = 5.78 x 10-04). Sex-stratified analysis also showed similar results as shown in S3 Table.
Association analysis for ACP vs. controls. In the ACP patients, all 5 variants in X-linked
CLDN2 andMORC4 genes showed significant association with ACP even after adjustment for
age and sex (Table 4). Similar to combined analysis, CLDN2 andMORC4 gene locus showed
conferment of susceptibility in ACP group with ORs ranging from 1.48 to 2.00 and P value
0.003 to 1.89 x 10-06 (Table 4).
Similar to the ICP patients, a significant association at PRSS1-PRSS2 locus with OR 0.55
(95% CI [0.39–0.79], P = 0.001) was present in ACP patients.
Combined risk analysis
The analysis based on the effective number of risk alleles of all 7 significant SNPs (at
p< 0.0055), revealed significantly enhanced risk of CP by 1.2 fold with increase in each unit of
‘effective’ risk allele (P = 7.3 x 10-08) (Fig 1). Individuals with 13 or more risk alleles carried
7.17 fold increased risk for CP compared with the individuals with 5 or less risk alleles
(P = 7.51 x 10-12).
Assessment of variation at CLDN2 andMORC4 locus
As, CLDN2, MORC4 genes are positioned closely and showed strongest association with risk of
CP, a detailed analysis of SNPs within the CLDN2 andMORC4 genes, termed CLDN2 and
MORC4 locus was performed. Homozygous individuals for risk alleles were more prevalent in
cases versus controls (Table 5). Having either one or more variation within the locus increased the
Table 3. Association of SNPs with CP in ICP cases (n = 434) and control (n = 1288) subjects.
CHR Gene (SNP) A1* A2 Frequency OR (95%CI) SE Punadj OR (95%CI) SE Padj
Cases Controls
7 PRSS1-PRSS2 (rs2855983) A G 0.58 0.66 0.69 (0.59–0.81) 0.08 4.57 x 10-06 0.63 (0.49–0.82) 0.13 5.78 x 10-04
8 SAMD12-TNFRSF11B (rs11988997) T C 0.06 0.09 0.60 (0.44–0.84) 0.17 2.20 x 10-03 0.54 (0.31–0.92) 0.28 0.02
10 KIAA1462-MTPAP (rs2995271) C T 0.38 0.35 1.15 (0.98–1.36) 0.08 0.09 1.08 (0.83–1.42) 0.14 0.56
X MUM1L1-CXorf57 (rs379742) T C 0.46 0.32 1.52 (1.33–1.73) 0.07 4.91 x 10-10 1.31 (1.06–1.62) 0.11 0.01
X CLDN2 (rs4409525) A G 0.70 0.47 1.86 (1.62–2.12) 0.07 1.24 x 10-19 1.57 (1.28–1.93) 0.10 1.36 x 10-05
X CLDN2 (rs12008279) G A 0.89 0.73 2.04 (1.68–2.48) 0.10 7.68 x 10-13 1.46 (1.12–1.91) 0.14 5.80 x 10-03
X MORC4 (rs12012022) T C 0.36 0.25 1.41 (1.23–1.61) 0.07 9.85 x 10-07 1.14 (0.92–1.43) 0.11 0.23
X MORC4 (rs6622126) A G 0.89 0.72 2.42 (1.91–3.06) 0.12 2.04 x 10-13 1.62 (1.16–2.25) 0.17 4.20 x 10-03
X MORC4 (rs12688220) T C 0.73 0.48 1.91 (1.65–2.21) 0.07 7.02 x 10-18 1.50 (1.20–1.87) 0.11 2.98 x 10-04
* Effect sizes of current study are presented with respect to the reported allele (A1) in the source study, for proxy SNPs the allele on same strand as that
of reported allele has been used. Significance achieved at P = 0.05/9 (α = 0.0055) after Bonferroni correction.
CHR = chromosome, SNP = single nucleotide polymorphism, A2 = Other allele, OR = odds ratio, CI = confidence interval, SE = Standard error,
Punadj = unadjusted analysis and Padj = adjusted analysis for covariates. Analysis is adjusted for sex and age.
doi:10.1371/journal.pone.0147345.t003
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risk of CP substantially by 3.40 fold (95% CI [2.00–6.17], P = 1.37 x 10-06) in cases. The combined
risk analysis of 4 significantly associated SNPs (at p< 0.0055), showed an increase in risk of CP
by 1.18 fold for increase in each unit of ‘effective’ risk allele (P = 1.08 x 10-05) (Fig 2) with 5.09 fold
enhanced risk in females with 7 (3.5 in males) or more effective number of risk alleles compared
with females with 3 (1.5 in males) or less effective number of risk alleles (P = 1.88 x 10-14).
Gene-Environment interaction analysis
Interaction of genetic variants with environmental factors showed significant effect of
rs12688220 (MORC4) with alcohol (OR 14.62 for interaction of homozygous and OR 1.51 for
Fig 1. Combined risk analysis to determine the effect of increase in number of ‘effective’ risk alleles with risk of CP.On y-axis OR and 95%CI are
plotted, corresponding to number of effective risk alleles on the x-axis. Number in parenthesis on the x-axis indicates Sample size in each category. For every
unit increase in the number of effective’ risk allele, the OR is 1.20 and P value 7.30 x 10-08.
doi:10.1371/journal.pone.0147345.g001
Table 4. Association of SNPs with CP in ACP cases (n = 85) and control (n = 1288) subjects.
CHR Gene (SNP) A1* A2 Frequency OR (95%CI) SE Punadj OR (95%CI) SE Padj
Cases Controls
7 PRSS1-PRSS2 (rs2855983) A G 0.51 0.66 0.53 (0.39–0.72) 0.16 5.94 x 10-05 0.55 (0.39–0.79) 0.18 1.20 x 10-03
8 SAMD12-TNFRSF11B (rs11988997) T C 0.04 0.09 0.43 (0.20–0.92) 0.39 0.03 0.46 (0.20–1.04) 0.42 0.06
10 KIAA1462-MTPAP (rs2995271) C T 0.44 0.35 1.46 (1.05–2.03) 0.17 0.02 1.54 (1.06–2.25) 0.19 0.02
X MUM1L1-CXorf57 (rs379742) T C 0.40 0.32 1.25 (0.95–1.65) 0.14 0.11 1.30 (0.99–1.70) 0.14 0.06
X CLDN2 (rs4409525) A G 0.69 0.47 1.84 (1.41–2.42) 0.14 9.75 x 10-06 1.82 (1.39–2.39) 0.14 1.14 x 10-05
X CLDN2 (rs12008279) G A 0.90 0.73 2.23 (1.44–3.46) 0.22 3.46 x 10-04 1.76 (1.19–2.60) 0.20 4.60 x 10-03
X MORC4 (rs12012022) T C 0.40 0.25 1.64 (1.26–2.13) 0.13 2.00 x 10-04 1.48 (1.14–1.93) 0.13 3.40 x 10-03
X MORC4 (rs6622126) A G 0.91 0.72 2.53 (1.52–4.20) 0.26 3.36 x 10-04 1.94 (1.25–3.00) 0.22 3.00 x 10-03
X MORC4 (rs12688220) T C 0.77 0.48 2.28 (1.69–3.08) 0.15 7.49 x 10-08 2.00 (1.50–2.66) 0.15 1.89 x 10-06
*Effect sizes of current study are presented with respect to the reported allele (A1) in the source study, for proxy SNPs the allele on same strand as that
of reported allele has been used. Significance achieved at P = 0.05/9 (α = 0.0055) after Bonferroni correction.
CHR = chromosome, SNP = single nucleotide polymorphism, A2 = Other allele, OR = odds ratio, CI = confidence interval, SE = Standard error,
Punadj = unadjusted analysis and Padj = adjusted analysis for covariates. Analysis is adjusted for age.
doi:10.1371/journal.pone.0147345.t004
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interaction of heterozygous risk allele, P = 0.0068) hence amplifying the risk of CP (Table 6).
No significant interaction of any other risk alleles was observed with either alcohol or smoking
in CP patients.
Discussion
In present study, we examined the association of 9 SNPs, identified in a recent GWAS on pan-
creatitis [10], in 1807 Indian subjects. Whitcomb et al., reported CLDN2 and PRSS1-PRSS2 loci
to be associated with recurrent acute pancreatitis and CP (predominantly alcohol-related
chronic pancreatitis) in North American subjects of European ancestry. This work confirms
association of variants in X-linked CLDN2 andMORC4 gene with risk susceptibility in Indian
patients with CP. The association might be more robust for CP since we included well charac-
terized patients with CP only and not those with recurrent acute pancreatitis.
GWAS by Whitcomb et al., recently reported association of CLDN2 gene variants with CP
in Chinese, European, Japanese and Indian patients [19–22]. Interestingly, our study confirms
Table 5. Comparison of SNPs atCLDN2 andMORC4 locus in CP cases and controls.
Cases Control
n % n %
Gene (SNP) Risk allele Total Hom Het Hom Het Total Hom Het Hom Het
CLDN2 (rs4409525) A 503 327 45 65.01 8.95 1284 446 295 34.74 22.98
CLDN2 (rs12008279) G 502 434 29 86.45 5.78 1282 829 230 64.66 17.94
MORC4 (rs12012022) T 498 128 109 25.70 21.89 1286 200 241 15.55 18.74
MORC4 (rs6622126) A 380 327 33 86.05 8.68 1286 801 240 62.29 18.66
MORC4 (rs12688220) T 441 283 70 64.17 15.87 1279 462 300 36.12 23.46
Hom = Homozygote for risk allele, Het = Heterozygote, n = Number of samples
doi:10.1371/journal.pone.0147345.t005
Fig 2. Combined risk analysis to determine the effect of increase in number of ‘effective’ risk alleles atCLDN2 andMORC4 loci with risk of CP.On
y-axis OR and 95%CI are plotted, corresponding to number of effective risk alleles on the x-axis. Number in parenthesis on the x-axis indicates Sample size
in each category. For every unit increase in the number of effective’ risk allele, the OR is 1.18 and P value 1.08 x 10-05.
doi:10.1371/journal.pone.0147345.g002
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the same in Indian CP patients of Indo-European ethnicity. CLDN2 gene codes for protein
claudin-2 that lies in tight junctions and immunohistochemical staining showed weak but
membrane-bound expression in acinar, ductal and islet cells in normal human pancreatic tis-
sue [23]. However, premalignant pancreatic cystic lesions showed a more robust expression of
claudin-2 suggesting that its aberrant form may directly interfere with tight junction formation
and function. Whether the variants in the gene might be related to impaired permeability,
affecting either acinar or ductal cells function remains to be explored. Additionally, CLDN2
promoter includes a nuclear factor κB (NF-κB) binding site [24] and a variant CLDN2might
have a role in NF-kB activation.
MORC4 shows wide spread expression in normal tissues including a weak but positive sig-
nal in human pancreas [25] and Liggins et al., identified its protein to contain a highly con-
served N-terminus, an ATPase domain that may indicate a functional requirement for ATP
hydrolysis, a zinc finger motif that may promote protein–protein or protein–nucleic acid inter-
actions and a CW zinc finger with a probable role with methylated DNA or chromatin [25]. A
Swedish study reported significant association between risk to Crohn's disease and SNP in
MORC4 (rs6622126, also significantly associated with CP in present study) using a case-control
approach [26]. Our findings suggest an increased risk of CP with variants inMORC4 gene in
addition to a high risk coupled with alcohol intake suggesting a strong gene environment inter-
action. Polymorphisms of alcohol metabolizing genes have not explained the susceptibility of
some individuals to develop pancreatitis. If proven, such a gene environment interaction could
explain individual susceptibility and possibly organ specificity. The downstream signaling of
MORC4 activation in pancreatitis needs exploration using experimental models but a protein-
protein interaction database (Protein Interaction Network Analysis; PINA) [27] suggests its
Table 6. Gene-Environment interaction of genetic variants with alcohol and smoking in CP.
Alcohol
OR Punadj OR Padj
Gene (SNP) Risk/ non-risk allele Homozygous Heterozygous Homozygous Heterozygous
PRSS1-PRSS2 (rs2855983) G/A 1.59 1.89 0.18 1.41 2.81 0.05
SAMD12-TNFRSF11B (rs11988997) C/T 1.17 - 0.54 1.54 - 0.19
MUM1L1-CXorf57 (rs379742) T/C 2.74 0.51 0.26 3.48 0.93 0.57
CLDN2 (rs4409525) A/G 2.56 0.80 0.61 8.94 2.14 9.80 x 10-03
CLDN2 (rs12008279) G/A 0.95 - 0.55 1.19 - 0.21
MORC4 (rs6622126) A/G 0.82 - 0.64 1.28 - 0.10
MORC4 (rs12688220) T/C 2.63 0.67 0.36 14.62 1.51 6.80 x 10-03
Smoking
OR Punadj OR Padj
Gene (SNP) Risk/ non-risk allele Homozygous Heterozygous Homozygous Heterozygous
PRSS1-PRSS2 (rs2855983) G/A 2.74 2.15 0.20 1.78 1.87 0.26
SAMD12-TNFRSF11B (rs11988997) C/T 1.30 - 0.71 1.59 - 0.32
MUM1L1-CXorf57 (rs379742) T/C 1.51 x 10-06 0.37 3.90 x 10-03 2.26 x 10-06 0.38 0.27
CLDN2 (rs4409525) A/G 3.32 x 10-06 1.08 0.49 4.75 x 10-06 1.47 0.27
CLDN2 (rs12008279) G/A 2.27 x 10-06 0.65 0.29 3.37 x 10-06 0.85 0.70
MORC4 (rs6622126) A/G 1.53 x 10-06 0.42 0.11 2.06 x 10-06 0.61 0.66
MORC4 (rs12688220) T/C 0.61 0.69 0.28 2.59 0.91 0.63
Risk allele is used for calculation of odds ratio and P value. Significance achieved at P = 0.05/7 (α < 0.0071) for the 7 significantly associated variants.
SNP = single nucleotide polymorphism, OR = odds ratio, Punadj = unadjusted analysis and Padj = adjusted analysis for covariates.
doi:10.1371/journal.pone.0147345.t006
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interaction with AMPKa1, GEMIN4, HECW2, SKIL, STAT3 and UBC, and downstream regu-
lation of all/either of these might be pathophysiologically relevant.
It seems likely that CLDN2 and/orMORC4 genes play an important pathophysiological role
in CP. Association of X-linked genetic variants with CP might be an important reason for male
predominance among the patients with CP as has also been suggested by Whitcomb et al [10].
Although gain-of-function mutations in gene for cationic trypsinogen (PRSS1) are well
established in hereditary pancreatitis in patients of different ethnicity [28,29], previous studies
in Indian patients with CP did not identify any significant mutations/polymorphisms in the
PRSS1 gene [11,12,30,31]. Interestingly, a loss-of-function mutation (p.G191R) in anionic tryp-
sinogen gene (PRSS2) has been reported protective against developing pancreatitis in Euro-
pean, Japan and Indian populations [32–35]. A current investigation identified a functional
promoter variant rs4726576C/A near rs10273639 to affect the expression of PRSS1 gene in
pancreatic tissue in mice [36]. Significant association of protective variant in PRSS1-PRSS2
locus in all three categorical analyses i.e. ICP and ACP combined as well as only ICP/ ACP ver-
sus controls suggesting a role of PRSS1-PRSS2 locus in Indian patients.
We also found significant association of variant (rs11988997) in SMAD12-TNFRSF11B con-
ferring a protective status to CP in our population. SAMD12 (Sterile Alpha Motif Domain con-
taining 12) proteins containing SAM domains show varied protein–protein interaction nodes,
though a conclusive function has not been assigned to this gene [37]. TNFRSF11B (gene for
osteoprotegerin, OPG) is a member of TNF-receptor super family and its expression was
shown to correlate with the aggressiveness of pancreatic ductal cell carcinoma [38]. Using a rat
beta cell line and human primary pancreatic islets, OPG was shown to prevent cytokine
induced p38 MAPK phosphorylation and subsequent beta cell death, and suggested to act as
an autocrine or paracrine survival factor for beta cells [39]. On the contrary, a recent study
demonstrated the role of serum OPG in promoting beta cell dysfunction in vivo in mice [40]
and therefore its role in pancreatic structure and function needs further investigation. There
are no other reports showing association of this gene with CP.
Conclusion
We replicated association of common variants in CLDN2,MORC4, PRSS1-PRSS2 and
SMAD12-TNFRSF11B loci with CP in Indians subjects of Indo-European origin and showed
significant association particularly with variants in theMORC4/CLDN2 locus. Further studies
through deep sequencing are required to identify the actual polymorphism/mutation associ-
ated with CP as are functional studies to elucidate the mechanism of injury.
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